In acute small vessel occlusion strokes, pre-existing chronic microvascular damage significantly alters how antiplatelet genetics affect early neurological deterioration, according to a retrospective observational cohort investigation conducted at Beijing Geriatric Hospital. Published in Annals of Clinical and Translational Neurology, the study evaluated whether white matter hyperintensities modify the clinical effect of CYP2C19 loss-of-function alleles among acute ischemic stroke patients treated with dual antiplatelet therapy consisting of aspirin and clopidogrel. Across a strictly defined cohort of two hundred forty-seven eligible patients, early neurological deterioration occurred in twenty-one point nine percent of cases within seventy-two hours of hospital admission. While carrying CYP2C19 loss-of-function variants alone did not independently predict neurological progression across the overall study cohort, researchers uncovered a prominent gene-imaging interaction. Specifically, carrying loss-of-function alleles was associated with more than a threefold increase in the risk of early neurological deterioration among individuals with severe white matter hyperintensity burden, whereas no significant increase in deterioration risk was observed among patients with mild white matter changes.
Small vessel occlusion accounts for roughly twenty-five percent of all acute ischemic strokes, commonly presenting with relatively mild initial neurological deficits that can nevertheless deteriorate rapidly during early hospitalization. Clinical records indicate that early neurological deterioration manifests in sixteen point nine percent to thirty point zero percent of patients with small vessel occlusion, frequently transforming manageable initial presentations into poor long-term functional recovery. Standard clinical practice relies upon guideline-recommended dual antiplatelet therapy, primarily combining aspirin and clopidogrel to suppress recurrent ischemia and halt progressive thrombosis. Despite this dual antiplatelet regimen, early neurological progression continues to emerge in a notable proportion of treated individuals, making targeted prevention an enduring clinical challenge. Pathophysiological investigations indicate that the underlying mechanisms generating early deterioration are complex and multifactorial, with local thrombus extension driven by persistent platelet activation serving as a primary contributor. Previous studies have identified numerous baseline risk factors, including initial stroke severity measured by the National Institutes of Health Stroke Scale, infarct size, lesion location, and capsular warning syndrome.
A substantial driver of residual thrombotic risk in acute small vessel occlusion stems from individual variability in clopidogrel responsiveness, commonly termed clopidogrel resistance. Because clopidogrel functions as an inactive prodrug, it requires two-step hepatic biotransformation mediated by cytochrome P450 enzymes, particularly CYP2C19, to generate its active, platelet-inhibiting thiol metabolite. Inherited loss-of-function alleles, predominantly CYP2C19*2 and CYP2C19*3, significantly diminish active metabolite production, leading to impaired platelet inhibition and an approximately doubled risk of early deterioration in affected carriers. These loss-of-function genetic variants are especially prevalent across East Asian populations, appearing in approximately sixty percent of individuals. Nevertheless, previous pharmacogenomic investigations have established that CYP2C19 genotype in isolation accounts for only ten to twelve percent of total clinical response variability during antiplatelet therapy. This modest explanatory power strongly implies that additional physiological traits, baseline anatomical vulnerabilities, or environmental factors must interact with inherited loss-of-function alleles to modulate antiplatelet efficacy and determine whether inadequate platelet suppression translates into overt clinical stroke progression.
White matter hyperintensities detected on brain magnetic resonance imaging serve as the quintessential neuroimaging hallmark of chronic cerebral small vessel disease. These radiological lesions reflect cumulative microvascular damage, progressive endothelial dysfunction, blood-brain barrier disruption, and chronically impaired cerebral hemodynamic regulation. Because white matter hyperintensities and acute small vessel occlusion share identical underlying microvascular pathology, a severe burden of white matter hyperintensities indicates exhausted baseline cerebrovascular reserve, impaired autoregulation, and compromised collateral perfusion. When an acute penetrating artery occlusion occurs within a chronically impaired vascular bed, pre-existing microvascular compromise leaves adjacent brain tissue exceptionally vulnerable to focal perfusion failure. The investigators therefore proposed a biological two-hit hypothesis: chronic microvascular injury and exhausted circulatory reserve represent a fragile first hit, while suboptimal platelet inhibition caused by CYP2C19 loss-of-function alleles acts as a second hit. Under this conceptual framework, even minor local thrombus propagation could precipitate irreversible perfusion collapse, whereas preserved microvascular reserve in mild white matter disease can effectively buffer against residual genetic risk.
To examine this postulated gene-imaging interaction, the research team conducted a retrospective analysis of twelve hundred eight acute ischemic stroke patients admitted to the Department of Neurology at Beijing Geriatric Hospital between January 2023 and December 2025. Strict eligibility criteria required admission within forty-eight hours of symptom onset, age of eighteen years or older, magnetic resonance confirmation of small vessel occlusion, complete imaging datasets for cerebral small vessel disease scoring, treatment with aspirin plus clopidogrel, and available CYP2C19 genotyping. The investigators excluded patients with other stroke etiologies, contraindications to dual antiplatelet therapy, pre-stroke modified Rankin Scale scores exceeding two, receipt of intravenous thrombolysis or endovascular thrombectomy, and incomplete baseline records. This systematic screening yielded an analytical cohort of two hundred forty-seven patients, among whom ninety-day follow-up was completed in two hundred forty individuals, representing ninety-seven point two percent retention. The final study cohort exhibited a median age of sixty-seven years, twenty-eight point seven percent female representation, and a CYP2C19 loss-of-function carrier frequency of sixty point seven percent.
All radiological assessments were performed using a three-tesla magnetic resonance scanner running diffusion-weighted imaging, fluid-attenuated inversion recovery, and susceptibility-weighted imaging sequences in accordance with the international STRIVE consensus. Two neuroradiologists blinded to clinical and genetic information evaluated white matter hyperintensities using the Fazekas scale, scoring periventricular and deep white matter lesions independently to generate a cumulative score from zero to six. Patients were stratified into mild white matter disease, defined as scores zero to two, and severe white matter disease, defined as scores three to six. A total cerebral small vessel disease score ranging from zero to four was also calculated, awarding one point each for lacunes, extensive white matter hyperintensities, cerebral microbleeds, and moderate-to-severe basal ganglia enlarged perivascular spaces. Infarct locations were categorized as strategic, involving the internal capsule, pons, or corona radiata, or non-strategic. Genotyping of CYP2C19*2, *3, and *17 was carried out from buccal swabs using the validated GMEX point-of-care system.
Univariate comparisons demonstrated that the fifty-four patients who experienced early neurological deterioration had significantly higher baseline stroke scale scores, larger infarct diameters, higher total cerebral small vessel disease scores, and a higher proportion of strategic infarct locations. Specifically, strategic lesions were present in seventy-five point nine percent of deteriorating patients compared to fifty-eight point five percent of non-deteriorating individuals. Admission systolic blood pressure was numerically higher in the deteriorating group, while age, sex, and traditional vascular risk factors did not differ significantly. In a multivariable logistic regression model adjusting for demographic factors, blood pressure, admission severity, smoking, alcohol use, glucose, and lesion characteristics, infarct diameter remained an independent predictor of deterioration, yielding an adjusted odds ratio of one point twenty-six per millimeter increase. However, when evaluated without interaction terms, severe white matter hyperintensities and CYP2C19 loss-of-function carrier status failed to achieve statistical significance on their own, demonstrating adjusted odds ratios of one point seventy-two and one point twenty-two, respectively.
A starkly different clinical pattern emerged once the researchers formally evaluated the multiplicative interaction between CYP2C19 loss-of-function carrier status and severe white matter hyperintensity burden. In the fully adjusted multivariable regression model, the cross-product interaction term achieved high statistical significance, with an adjusted odds ratio of nine point thirty-four and a ninety-five percent confidence interval ranging from two point zero six to forty-eight point ten. Likelihood ratio testing corroborated this finding with an interaction p-value of zero point zero zero three four. Additive interaction metrics likewise demonstrated biological synergy, yielding a relative excess risk due to interaction of one point sixty-five and an attributable proportion of one point fifteen. Stratified subgroup analyses further illustrated this modification: among patients with mild white matter hyperintensities, loss-of-function status was not significantly associated with early deterioration, whereas among patients with severe white matter hyperintensities, loss-of-function carriers faced a statistically significant adjusted odds ratio of three point forty-four.
When evaluating the Fazekas score on a continuous scale, the statistical interaction term did not achieve formal significance, yet predicted probability curves demonstrated a clear intersection at a Fazekas score of approximately two point seventy. Beyond this inflection point, the predicted probability of early neurological deterioration rose much more steeply among loss-of-function carriers than among non-carriers, supporting a threshold effect where clinical consequences of clopidogrel resistance emerge predominantly once baseline microvascular damage crosses into severe classification. Regarding secondary clinical outcomes, severe early neurological deterioration occurred in six point seven percent of loss-of-function carriers and five point two percent of non-carriers. Favorable ninety-day functional outcomes, defined as modified Rankin Scale scores of zero to two, were attained by ninety-five point two percent of carriers and ninety-seven point eight percent of non-carriers. Safety events were remarkably infrequent across the cohort, with symptomatic intracranial hemorrhage documented in only three patients, a single minor bleeding episode, and no all-cause mortality recorded during ninety-day follow-up.
Despite these compelling findings, the investigators emphasized several methodological limitations that warrant careful interpretation before translating findings into routine practice. The single-center, retrospective observational design focused exclusively on a Chinese population, which may constrain generalizability to other ethnic cohorts with differing genetic allele frequencies or small vessel disease prevalence. Additionally, while visual Fazekas scoring reflects routine clinical feasibility, it lacks the precision of volumetric neuroimaging quantification. The anatomical inclusion criteria allowed infarct diameters up to twenty millimeters, which likely incorporated cases of branch atheromatous disease alongside classic lipohyalinotic small vessel occlusion. Furthermore, clinical fluctuations characteristic of capsular warning syndrome were not systematically captured, and genotyping omitted rarer CYP2C19 alleles, alternative antiplatelet genes, and direct laboratory platelet function assays. Treatment escalation occurred in ninety-two point six percent of deteriorating patients through tirofiban or ticagrelor administration, introducing therapeutic heterogeneity. Consequently, the authors concluded that prospective multicenter clinical trials are essential to validate this gene-imaging interaction and determine whether genotype-guided alternative antiplatelet strategies improve outcomes.
Subject of Research: Interaction between white matter hyperintensities and CYP2C19 loss-of-function variants in small vessel occlusion
Article Title: White Matter Hyperintensities Modify CYP2C19 Effect on Stroke Progression in Small Vessel Occlusion
Article References: Sun, X., Liu, X., Wang, L., Zhu, R., Wang, M., & Zhang, Z. (2026). White Matter Hyperintensities Modify CYP2C19 Effect on Stroke Progression in Small Vessel Occlusion. Annals of Clinical and Translational Neurology, Article acn3.70579. https://doi.org/10.1002/acn3.70579
Image Credits: AI Generated
DOI: 10.1002/acn3.70579
Keywords: small vessel occlusion, white matter hyperintensities, CYP2C19 loss-of-function, early neurological deterioration, dual antiplatelet therapy, clopidogrel resistance, cerebral small vessel disease, Fazekas scale, ischemic stroke progression, aspirin and clopidogrel, infarct diameter, lacunar stroke, pharmacogenomics, neuroimaging biomarkers, Beijing Geriatric Hospital, modified Rankin Scale, perfusion failure
News Source: Cassandra Pierce. (November 20, 2026). Severe White Matter Damage Amplifies Stroke Progression in CYP2C19 Gene Carriers. Scienmag.



